Clinical trials: Biliary Cancers
Biliary Tract Cancer (BTC)
Bile ctDNA Genomic Profiling and Concordance With Tumor Tissue in Biliary Tract Cancer
This study is being done to find out whether bile fluid can be used to detect genetic changes in tumors of patients with advanced biliary tract cancer (BTC), such as cancer of the bile ducts or gallbladder.
- Trial name
- NCT07830628
- Testing
- Bile Sampling for ctDNA Analysis
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- CHA University
Cholangitis, Secondary Biliary, Cholangiocarcinoma
Advanced Endoscopy During COVID-19
In this study, investigators aim to explore the status of advanced endoscopy in different endoscopy units all over the world.
- Conditions
- Cholangitis, Secondary Biliary, Cholangiocarcinoma, Obstructive Jaundice, Pancreas Cancer
- Trial name
- NCT04385147
- Testing
- Endoscopic management according to standard of care
- Where
- 5 sites in United States, Egypt and 3 more
- Volunteers
- 670 people
- Sponsor
- Al-Azhar University
Choledochal Cyst
A Longitudinal Cohort Study on the Changes of Physiological Mechanisms in Children After Biliary Tract Reconstruction
Through observational studies, the long-term changes in liver function, metabolic state, immune response and other aspects of children after biliary tract reconstruction during their growth process were systematically explored.
- Trial name
- NCT07530354
- Where
- 3 sites in China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Wuhan Children's Hospital
Biliary Tract Neoplasms Immunotherapy
Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer
An investigation into the survival outcomes, progression-free survival, and safety of triple therapy with Trastuzumab Rezetecan, Adebrelimab, and Lenvatinib in patients with advanced HER2-positive/low-expressing biliary tract…
- Trial name
- NCT07704177
- Testing
- Trastuzumab Rezetecan, Adebrelimab, Lenvatinib
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking Union Medical College Hospital
Biliary Tract Cancer
Molecular Profiling of Advanced Biliary Tract Cancers
Biliary tract cancer (BTC) accounts for <1% of all cancers, but remains a highly fatal malignancy. Surgical resection is the only hope for cure, but most patients present with advanced disease when curative-intent surgery is not…
- Trial name
- COMPASS-B-MUHC (NCT04318834)
- Testing
- Tumour and germline molecular profiling
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Pancreatic Cancer, Lung Cancer, Nonsmall Cell
Study of PRO in Patients With Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)
Pancreatic and biliary tract cancer are ones of the leading causes of cancer-related deaths. During the course of illness, these patients often experience marked physical suffering, psychological distress and frequent unplanned…
- Trial name
- BetterEveryDay (NCT04611867)
- Testing
- Supportive application with integrated weekly PRO
- Where
- Denmark
- Volunteers
- 274 people
- Sponsor
- Inna Chen, MD
Gallbladder Cancer
Evaluation of the Effectiveness of Intraoperative Frozen Section on the Treatment of Suspected Gallbladder Cancer
Evaluate the effectiveness of intra-operative frozen section in the treatment of gallbladder cancer. The study will be looking in to identify if intraoperative frozen section is a viable method to intraoperatively evaluate the…
- Trial name
- NCT06189664
- Testing
- Frozen section
- Volunteers
- 37 people
- Sponsor
- Imperial College London
Advance Solid Tumors, Colon and Rectal Cancer
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations
This is a Phase 1 and Phase 2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of INV-8989 in patients with advanced solid tumors harboring KRAS G12D mutations.
- Conditions
- Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced or Metastatic
- Trial name
- NCT07610798
- Testing
- INV-8989
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Malignant Hepatobiliary Neoplasm
Endoscopic Ultrasonography Guided Biliary Drainage
Endoscopic ultrasonography is a widely accepted modality for the diagnosis of gastrointestinal and pancreatic-biliary diseases. Endoscopic ultrasonography-guided biliary drainage has attracted attention as an alternative…
- Trial name
- NCT03195075
- Testing
- Endoscopic ultrasonography guided biliary drainage, Percutaneous trans-hepatic biliary drainage
- Volunteers
- 40 people
- Sponsor
- Assiut University
Pancreatic Neoplasms, Bile Duct Neoplasms
Evaluation of Isolated Roux-en-Y Reconstruction After Pancreaticoduodenectomy
The purpose of this study is to evaluate the incidence of complications with the isolated Roux-en-Y reconstruction after pancreaticoduodenectomy in pancreatic tumor and periampullary tumor patients.
- Conditions
- Pancreatic Neoplasms, Bile Duct Neoplasms, Ampullary Neoplasms, Duodenal Neoplasms
- Trial name
- NCT00915863
- Testing
- Billroth-II-type reconstruction, Isolated Roux-en-Y type reconstruction
- Where
- Japan
- Volunteers
- 150 people
- Sponsor
- Wakayama Medical University
Cholangiocarcinoma of the Extrahepatic Bile Duct, Gallbladder Cancer
Molecularly Target Therapy With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
The purpose of this study is to evaluate the feasibility, efficacy and safety of target therapy according to genomic and proteomic profiling combined with FORFIRINOX in advanced or recurrent extrahepatic cholangiocarcinoma and…
- Trial name
- NCT03768375
- Testing
- conventional chemotherapy(FORFIRINOX) combined with target agents, conventional chemotherapy(FORFIRINOX)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Radiofrequency Ablation, Biliary Tract Cancer
Endoluminal Radiofrequency Ablation for the Treatment of Malignant Biliary Stenosis
The rationale of the study is to explore the safety and efficacy of endoluminal radiofrequency ablation prior metal stent insertion in patiens with malignant biliary stenosis.
- Conditions
- Radiofrequency Ablation, Biliary Tract Cancer, Stent Complication, Brachytherapy
- Trial name
- NCT04801719
- Testing
- Habib™ EndoHPB; Boston Scientific, US; former EMcision Ltd., UK
- Where
- Czechia
- Volunteers
- 76 people
- Sponsor
- Brno University Hospital
Cholangiocarcinoma
A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors
Biliary tract cancer (BTC) accounts for 4% of the malignant tumors of the digestive system, and the incidence has increased significantly in recent years.
- Trial name
- NCT04866836
- Testing
- Radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Cholangiocarcinoma, Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
Bile Omics for Diagnosing Indeterminate Biliary Strictures
The diagnosis of malignant biliary strictures remains a challenging aspect of biliary endoscopy. Molecular biological testing techniques based on bile have been reported to improve detection rates.
- Conditions
- Cholangiocarcinoma, Gallbladder Cancer and Extrahepatic Cholangiocarcinoma, Pancreatic Cancer, Bile Duct Strictures of Unknown Origin
- Trial name
- NCT07007832
- Testing
- Endoscopic retrograde cholangiopancreatography
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Biliary Tract Cancer
Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer
To compare efficacy and safety of Gemcitabine versus S-1 adjuvant therapy after hemihepatectomy.
- Trial name
- NCT01815307
- Testing
- Gemcitabine, S-1
- Where
- Japan
- Volunteers
- 70 people
- Sponsor
- Kansai Hepatobiliary Oncology Group
Cholangiocarcinoma
Endobiliary Radiofrequency Ablation With S-1 for Unresectable Cholangiocarcinoma
Endobiliary radiofrequency ablation (RFA) with biliary stent has been reported to be a beneficial treatment option for palliation of malignant biliary strictures.
- Trial name
- NCT02592538
- Testing
- radiofrequency ablation, S-1, Stent
- Where
- China
- Volunteers
- 66 people
- Sponsor
- First People's Hospital of Hangzhou
Malignant Biliary Obstruction, Hepatocellular Carcinoma
Efficacy and Safety of a Fully Covered Self-Expandable Metal Stent for Unresectable HCC
The effectiveness and safety of fully covered metal stent in malignant biliary obstruction caused by HCC are still unknown. These would be clarified in this prospective cohort study.
- Trial name
- NCT05729867
- Testing
- Endoscpic biliary drainage using fully covered metal stent
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- Seoul National University Hospital
Biliary Tract Cancer
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
The primary purpose of this study is to investigate the safety of Tasfygo.
- Trial name
- NCT06793709
- Testing
- No Intervention
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Eisai Co., Ltd.
Cholangiocarcinoma, Pancreas Cancer
RFA for Malignant Biliary Obstruction
Pancreatic cancer and cholangiocarcinoma are the most common causes of malignant biliary obstruction. They are diseases of increasing incidence and unfavorable prognosis.
- Trial name
- NCT03166436
- Testing
- Radiofrequency ablation, Biliary stenting
- Where
- Czechia
- Volunteers
- 140 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Cholangiocarcinoma
Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
Patients with advanced or metastatic cholangiocarcinoma (CCA) who are not eligible for curative surgery, transplantation, or ablative therapies will receive nab-paclitaxel and gemcitabine chemotherapy.
- Trial name
- PrE0204 (NCT02181634)
- Testing
- Nab-Paclitaxel and Gemcitabine
- Where
- 25 sites in United States, Austria
- Volunteers
- 74 people
- Sponsor
- PrECOG, LLC.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.